Early DiaGnosis of Anoxic Brain Injury for Resuscitated Patients (EDGAR)

Evaluation of Early Prognosis Factors of Neurological Evolution After Resuscitated Cardiac Arrest in Adults

Sudden cardiac arrest (CA) in adults remains a major public health issue in industrialized countries, leading to a mortality rate greater than 90%. The analysis of French data estimates the number of sudden deaths at around 40,000 per year. The incidence rate for non-hospital CAs is 55 per 100,000 every year with an immediate survival rate of 9% and 4.8% at one year.

Study Overview

• Status: Suspended
• Conditions: Cardiac Arrest

Detailed Description

Approximately 80 % of patients who survive CA with cardiopulmonary resuscitation are comatose. The longer it lasts, the lower chances of recovery. The evaluation of the neurological prognosis of these patients is an important issue. Indeed, 72% of patients admitted to an intensive care unit after resuscitation from CA will give rise to an ethical discussion with the family. The prognostication strategy is usually based on a multimodal process involving clinical examination, electro-neurophysiological and biological examinations. We plan to study the relevance of early neurological prognostic tests in the aftermath of CA and in particular the most recent techniques such as the use of a clinical score (CAHP for Cardiac Arrest Hospital Prognosis), automated infrared pupillometry (NEUROLIGHT ALGISCAN, IDMED) for pupillary reflex measurement and quantitative analysis of the continuous amplitude-integrated electroencephalogram (aEEG) BRAIN QUICK ICU LINE, MICROMED. These new prognostic criteria for CA (CAHP score, pupillometry and aEEG) developed separately have not yet been integrated into a multimodal strategy.

The goal of this study is to evaluate the performance of CAHP score, infrared automated pupillometry and aEEG to predict as early as 24h from ROSC the neurological prognosis (Cerebral Performance Categories) at hospital discharge.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Rostane GACI, MD; Phone Number: 0033 387186220; Email: r.gaci@chr-metz-thionville.fr
• Study Contact Backup: Name: Serge Le Tacon, MD; Phone Number: 0033 387186235; Email: s.le-tacon@chr-metz-thionville.fr

Study Locations

• France
  • Metz, France, 57085
    • CHR Metz Thionville

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Every major patient admitted in the Mercy Hospital CHR Metz-Thionville intensive care unit after CA

Description

Inclusion Criteria:

• Admission in Intensive Care Unit (ICU) following cardiac arrest with ROSC

Exclusion Criteria:

• Minor patient
• Cardiac arrest (CA) occuring in ICU
• Decision before ICU admission to withdraw life-sustaining treatments
• Patient with post-ROSC Glasgow Coma Score = 15

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cerebral Performance Categories (CPC) score	The Cerebral Performance Categories (CPC) score is evaluated by a physician at hospital discharge (CPC baseline assessed on basal statut before CA). Good neurological outcome defined as CPC <3. CPC 1: no or minor disability (conscious and independent, able to work and lead a normal life. May have mild dysphasia, non-incapacitating hemiparesis, or minor cranial nerve abnormalities). CPC 2: Moderate disability (Conscious and independent, able to travel by public transport and work in sheltered environment, independent in activities of daily life. May have hemiplegia, seizures, ataxia, dysarthria or memory changes). Poor neurological outcome defined as CPC 3-5. CPC 3: severe disability (conscious but dependent, limited cognition, dementia, locked-in, minimally conscious. Usually in institution, but sometimes looked after at home with exceptional family effort). CPC 4: unconscious (persistent vegetative state). CPC 5: dead (certified brain dead or traditional criteria).	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cardiac Arrest Hospital Prognosis (CAHP) Score	Seven variables independently associated with poor neurological outcome (age, non-shockable rythm, time from collapse to basic life support, time from basic life support to return of spontaneous circulation, location of cardiac arrest, epinephrine dose and arterial pH)	Day 1
Pupillary light reflex surveillance with automated infrared pupillometry	Bilateral testing by trained nurse (3 measures, best result between the 2 eyes considered)	Day 1
Neuron Specific Enolase (NSE) plasmatic levels	Neuron Specific Enolase (NSE) plasmatic levels (ng/ml)	Day 2
Neuron Specific Enolase (NSE) plasmatic levels	Neuron Specific Enolase (NSE) plasmatic levels (ng/ml)	Day 3
Amplitude-integrated electroencephalography (aEEG)	Amplitude-integrated electroencephalography (aEEG) with Hellstrom-Westas classification	Day 1

Collaborators and Investigators

• Sponsor: Centre Hospitalier Régional Metz-Thionville

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2018
• Primary Completion (Estimated): September 1, 2024
• Study Completion (Estimated): September 1, 2025

Study Registration Dates

• First Submitted: December 12, 2018
• First Submitted That Met QC Criteria: January 15, 2019
• First Posted (Actual): January 16, 2019

Study Record Updates

• Last Update Posted (Estimated): February 23, 2024
• Last Update Submitted That Met QC Criteria: February 22, 2024
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: biomarkers; prognosis; Cardiac Arrest; Coma; electroencephalography; pupillary reflex; evoked potentials; targeted temperature management; hypoxic brain damage; neurological examination; clinical score
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Arrest
• Other Study ID Numbers: 2018-06Obs-CHRMT

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No